NCT05367401 2024-04-11A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS ParticipantsNovartisPhase 1/2 Withdrawn
NCT04283526 2021-03-04Study of Select Combinations in Adults With MyelofibrosisNovartisPhase 1 Withdrawn